Silence Therapeutics (NASDAQ:SLN - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.1850) per share and revenue of $1.2550 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 2:00 AM ET.
Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings results on Friday, March 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.07. Silence Therapeutics had a negative return on equity of 101.71% and a negative net margin of 15,851.88%.The business had revenue of $0.03 million during the quarter, compared to analysts' expectations of $2.19 million. On average, analysts expect Silence Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Silence Therapeutics Stock Up 3.1%
Silence Therapeutics stock opened at $7.36 on Thursday. The stock has a 50-day simple moving average of $6.37 and a 200 day simple moving average of $6.15. Silence Therapeutics has a 12-month low of $3.54 and a 12-month high of $8.40. The stock has a market capitalization of $347.61 million, a price-to-earnings ratio of -3.94 and a beta of 1.52.
Hedge Funds Weigh In On Silence Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Opaleye Management Inc. acquired a new position in Silence Therapeutics in the fourth quarter valued at about $480,000. Marshall Wace LLP lifted its stake in Silence Therapeutics by 87.1% in the fourth quarter. Marshall Wace LLP now owns 155,680 shares of the company's stock valued at $947,000 after buying an additional 72,461 shares during the period. Bank of Montreal Can lifted its stake in Silence Therapeutics by 4.4% in the fourth quarter. Bank of Montreal Can now owns 160,474 shares of the company's stock valued at $976,000 after buying an additional 6,692 shares during the period. Millennium Management LLC lifted its stake in Silence Therapeutics by 50.3% in the third quarter. Millennium Management LLC now owns 298,512 shares of the company's stock valued at $1,549,000 after buying an additional 99,865 shares during the period. Finally, Boothbay Fund Management LLC lifted its stake in Silence Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 279,637 shares of the company's stock valued at $1,451,000 after buying an additional 27,216 shares during the period. Institutional investors and hedge funds own 98.73% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have weighed in on SLN shares. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 13th. William Blair reissued an "outperform" rating on shares of Silence Therapeutics in a report on Monday, March 2nd. Jefferies Financial Group raised Silence Therapeutics to a "strong-buy" rating in a report on Wednesday, March 18th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $34.50.
Read Our Latest Report on Silence Therapeutics
About Silence Therapeutics
(
Get Free Report)
Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.
The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Silence Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silence Therapeutics wasn't on the list.
While Silence Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
